News

News

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform.

Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform. OBI Pharma, Inc. (TPEx: 4174) today announced preclinical …

News

OBI Pharma to present the Study Results of OBI-992 at the 14th World ADC London

OBI Pharma is excited to announce that Dr. Ming-Tain Lai, Chief Scientific Officer, has been invited to present an oral presentation at the upcoming 14th World ADC …

News

OBI announces the termination of OBI-3424 Phase II trial

Following a strategic portfolio review, the Board of Directors of OBI Pharma, Inc. (4174) has decided to terminate the OBI-3424-001 trial today (March 11, 2024), …

News

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody –  drug conjugate (ADC) targeting TROP2. Dosing of first patient in …

News

Kung-Yee Liang, PH.D. was elected as the chairman of OBI Pharma, Inc.

OBI Pharma, Inc. (4174.TWO) held a board meeting today (29th) and unanimously elected Kung-Yee Liang PH.D., the new legal representative, former president of the National …